Literature DB >> 8390815

Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.

S Safrin1, T Schacker, J Delehanty, E Hill, L Corey.   

Abstract

The thiocarbonohydrazone 348U87 inactivates herpes simplex virus ribonucleotide reductase and potentiates the activity of acyclovir against wild-type and acyclovir-resistant strains of herpes simplex virus. We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study. Transient improvement with combination therapy occurred frequently; however, target lesions reepithelialized completely in only 1 of 10 patients. Termination of study drug therapy was most often due to cessation of therapeutic effect before complete resolution of lesions. As currently formulated, topical 348U87 offers little therapeutic benefit for this indication.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8390815      PMCID： PMC187867          DOI： 10.1128/AAC.37.5.975

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbonyl]-thiocarbonohydrazone (348U87).

Authors:  T Spector; J A Harrington; D J Porter
Journal:  Biochem Pharmacol       Date:  1991-06-21       Impact factor: 5.858

2.  Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target.

Authors:  J M Cameron; I McDougall; H S Marsden; V G Preston; D M Ryan; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

3.  A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents.

Authors:  C McLaren; M N Ellis; G A Hunter
Journal:  Antiviral Res       Date:  1983-11       Impact factor: 5.970

4.  2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.

Authors:  T Spector; J A Harrington; R W Morrison; C U Lambe; D J Nelson; D R Averett; K Biron; P A Furman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Authors:  M N Ellis; D C Lobe; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes.

Authors:  A E Nilsen; T Aasen; A M Halsos; B R Kinge; E A Tjøtta; K Wikström; A P Fiddian
Journal:  Lancet       Date:  1982-09-11       Impact factor: 79.321

7.  A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo.

Authors:  J P Luby; J W Gnann; W J Alexander; V A Hatcher; A E Friedman-Kien; R J Klein; H Keyserling; A Nahmias; J Mills; J Schachter
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

8.  Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.

Authors:  T Spector; D C Lobe; M N Ellis; T A Blumenkopf; G M Szczech
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Treatment of resistant herpes simplex virus with continuous-infusion acyclovir.

Authors:  J P Engel; J A Englund; C V Fletcher; E L Hill
Journal:  JAMA       Date:  1990 Mar 23-30       Impact factor: 56.272

10.  Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.

Authors:  S L Sacks; J Portnoy; D Lawee; W Schlech; F Y Aoki; D L Tyrrell; M Poisson; C Bright; J Kaluski
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226
View more
  3 in total

1.  Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.

Authors:  Sukhada Bhave; Howard Elford; Michael A McVoy
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

Review 2.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

3.  High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi.

Authors:  Jean A Bernatchez; Emily Chen; Mitchell V Hull; Case W McNamara; James H McKerrow; Jair L Siqueira-Neto
Journal:  Microorganisms       Date:  2020-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.